Provectus Biopharmaceuticals Inc (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -828 | -3,555 | -2,822 | -2,109 | -1,031 |
| Depreciation Amortization | 2 | 11 | 9 | 6 | 3 |
| Accounts payable and accrued liabilities | -186 | 807 | 654 | 607 | 310 |
| Other Working Capital | 190 | 446 | 482 | 602 | 411 |
| Other Operating Activity | 198 | -751 | -609 | -576 | -285 |
| Operating Cash Flow | $-624 | $-3,042 | $-2,287 | $-1,470 | $-592 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 600 | 1,628 | 1,060 | 550 | 50 |
| Other Financing Activity | -84 | -260 | -166 | -153 | -84 |
| Financing Cash Flow | $516 | $1,368 | $894 | $397 | $-34 |
| Exchange Rate Effect | -2 | -2 | -3 | -1 | 0 |
| Beginning Cash Position | 1,432 | 3,107 | 3,107 | 3,107 | 3,107 |
| End Cash Position | 1,322 | 1,432 | 1,711 | 2,033 | 2,481 |
| Net Cash Flow | $-110 | $-1,675 | $-1,396 | $-1,074 | $-626 |
| Free Cash Flow | |||||
| Operating Cash Flow | -624 | -3,042 | -2,287 | -1,470 | -592 |
| Free Cash Flow | -624 | -3,042 | -2,287 | -1,470 | -592 |